arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Lucid Diagnostics Inc.

LUCD
$0.96 ▼ -0.04 (-4.46%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
7 Visible periods
24 Metrics
Absolute Benchmarks
Price Chart
38
Health
Weak
Bearish Absolute basis
auto_awesome

Analytical Summary

On an absolute basis, Lucid Diagnostics Inc. shows weak fundamentals, weighed down by Return on Invested Capital and FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $97.9M
Dividend Yield
Revenue Growth 8.3%
Op. Margin
ROIC -453.9%
FCF / Share $-0.46
Trailing P/E
Price / Book 11.5x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 6, 2026.

7-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$4.71M
↑ +8.3%
Net Income Profit after all expenses
$-58.01M
↓ -27.4%
FCF / Share Free cash flow per share
$-0.46
↑ +47.9%

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Invested CapitalReturn on Invested Capital of -453.9% is weak on an absolute basis (target > 10%)
  • FCF / Net IncomeFCF / Net Income of 0.80x is caution on an absolute basis (target > 1x)

Health Breakdown

Cash Quality
38

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 25 quarters